CD274 and neoplasm: Fraser et al. [92] demonstrated in two distinct mice models (CT-26 and MC-38 model) that the combination of BTH-1677 with anti-PD-1 or anti-PD-L1 agents is able to repress tumor growth, compared to models treated only with BTH-1677 or anti-PD-1/anti-PD-L1.